Target intelligence / Profile preview

Stomach volume occupancy

Molecular classification
Other
01

Overview

"Stomach volume occupancy" refers to the **physical capacity of the stomach to hold food and liquid**, rather than a discrete molecular entity such as a receptor, enzyme, or transporter. The human stomach is highly distensible; its resting empty volume is about the size of a fist but can expand to accommodate up to 4 liters in extreme cases[3][7]. The degree of stretch sends signals via nerves in the stomach wall to the brain's hypothalamus, contributing to sensations of fullness and satiety[7]. This physiological property plays an important role in regulating meal size and caloric intake. Increased fasting gastric volumes are associated with obesity and certain eating disorders like bulimia; conversely, reducing functional gastric capacity—through bariatric surgery or pharmacologic agents that slow gastric emptying—can reduce calorie intake by promoting earlier satiation[1]. However, "stomach volume occupancy" itself is not considered a therapeutic target at the molecular level but rather describes an anatomical/physiological state influenced by multiple factors including hormones (e.g., ghrelin), neural input, mechanical properties of smooth muscle tissue, and medical interventions[5][7]. In summary: "Stomach volume occupancy" is **not** a canonical drug target such as a receptor or enzyme. It represents an anatomical/functional concept relevant for understanding appetite regulation but does not correspond to any specific molecule suitable for direct pharmacological targeting.

02

Mechanism of action

Modulation of stomach volume through hormonal or surgical/endoscopic interventions to influence satiety and caloric intake[1]

03

Biological functions

Other (physiological parameter, not a molecular target)
04

Disease associations

Obesity (as a physiological factor influencing calorie intake)[1]Eating disorders (e.g., bulimia, binge-eating disorder)[1]
05

Safety considerations

Surgical or endoscopic reduction of stomach volume carries procedural risks[1]Pharmacologic modulation may have gastrointestinal side effects such as nausea, bloating, or altered motility[1]
06

Interacting drugs

Liraglutide (a GLP-1 receptor agonist that affects gastric emptying and maximum tolerated volume)[1]

1 more in the full profile.

Beyond the preview

Go deeper on Stomach volume occupancy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stomach volume occupancy.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call